Dr Reddy’s Laboratories is currently trading at Rs 1277.70, up by 30.15 points or 2.42% from its previous closing of Rs 1247.55 on the BSE. The scrip opened at Rs 1255.05 and has touched a high and low of Rs 1287.90 and Rs 1255.05 respectively. So far 160774 shares were traded on the counter. The … Read more
Dr. Reddy’s Laboratories is currently trading at Rs. 5551.05, up by 74.55 points or 1.36% from its previous closing of Rs. 5476.50 on the BSE. The scrip opened at Rs. 5535.00 and has touched a high and low of Rs. 5613.85 and Rs. 5425.00 respectively. So far 36005 shares were traded on the counter. The … Read more
Dr. Reddy’s Laboratories’ wholly owned subsidiary — Aurigene Discovery Technologies (Aurigene) and Olema Pharmaceuticals, Inc (Olema) have entered into exclusive global license agreement to research, develop and commercialize novel small molecule inhibitors of an undisclosed oncology target. Under the terms of the agreement, Olema will make an upfront licensing payment of $8 million for rights … Read more
Dr. Reddy’s Laboratories has launched Sevelamer Carbonate for Oral Suspension, in 0.8 g and 2.4 g packets, a therapeutic equivalent generic version of Renvela (sevelamer carbonate) for Oral Suspension, approved by the U.S. Food and Drug Administration (USFDA). The Renvela brand and generic had U.S. sales of approximately $101 million MAT for the most recent … Read more
The US Food and Drug Administration (USFDA) has completed the audit of Dr. Reddy’s Laboratories’ Formulations Srikakulum Plant (SEZ) Unit II, Andhra Pradesh on November 16, 2018 with zero observations. Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India … Read more
